AbbVie plans to build its first manufacturing site in Asia, with a Singapore production facility due to open its doors in 2019.
AbbVie recently announced plans to spend nearly £200m on a new production facility in Singapore – the company’s first manufacturing site in Asia.
The build in Singapore will increase the company’s capacity for producing the emerging compounds developed by their oncology and immunology division, with the Asian facility to be used to manufacture small molecules and biologics active drug substances.
Dr Azita Saleki-Gerhardt, senior vice-president of operations at AbbVie, said: “Our presence in Singapore will help assure geographic balance and continuity of product supply, as well as increased capacity to deliver on our growing biologics and small molecule product pipeline.”
It will also allow AbbVie to increase its influence in Asia, better supplying customers in the region and ensuring the company is well-placed to maximise on the emerging markets of the region.
While AbbVie already has a presence in Singapore, the new production base will boost the number of employees by 250 and ensure the company establishes a firm geographical foothold in the region.
The facility is set to be fully operational by 2019.